Neurogene Statistics
Total Valuation
Neurogene has a market cap or net worth of $548.55 million. The enterprise value is $394.37 million.
| Market Cap | 548.55M |
| Enterprise Value | 394.37M |
Important Dates
The next estimated earnings date is Thursday, August 15, 2024, after market close.
| Earnings Date | Aug 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Neurogene has 12.98 million shares outstanding. The number of shares has increased by 3,798.26% in one year.
| Shares Outstanding | 12.98M |
| Shares Change (YoY) | +3,798.26% |
| Shares Change (QoQ) | +262.98% |
| Owned by Insiders (%) | 12.99% |
| Owned by Institutions (%) | 17.07% |
| Float | 2.75M |
Valuation Ratios
The trailing PE ratio is 6.10.
| PE Ratio | 6.10 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.21 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.74, with a Debt / Equity ratio of 0.09.
| Current Ratio | 14.74 |
| Quick Ratio | n/a |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,601.27 |
Financial Efficiency
Return on equity (ROE) is -30.50% and return on invested capital (ROIC) is -31.76%.
| Return on Equity (ROE) | -30.50% |
| Return on Assets (ROA) | -26.00% |
| Return on Capital (ROIC) | -31.76% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$428,945 |
| Employee Count | 91 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +220.15% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +220.15% |
| 50-Day Moving Average | 36.20 |
| 200-Day Moving Average | 28.56 |
| Relative Strength Index (RSI) | 57.29 |
| Average Volume (20 Days) | 194,825 |
Short Selling Information
The latest short interest is 1.07 million, so 8.24% of the outstanding shares have been sold short.
| Short Interest | 1.07M |
| Short Previous Month | 1.06M |
| Short % of Shares Out | 8.24% |
| Short % of Float | 38.83% |
| Short Ratio (days to cover) | 0.09 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -59.23M |
| Pretax Income | -39.03M |
| Net Income | -39.03M |
| EBITDA | -34.67M |
| EBIT | -39.02M |
| Earnings Per Share (EPS) | $6.93 |
Balance Sheet
The company has $169.87 million in cash and $15.70 million in debt, giving a net cash position of $154.18 million or $11.88 per share.
| Cash & Cash Equivalents | 169.87M |
| Total Debt | 15.70M |
| Net Cash | 154.18M |
| Net Cash Per Share | $11.88 |
| Equity (Book Value) | 170.78M |
| Book Value Per Share | 13.16 |
| Working Capital | 162.32M |
Cash Flow
In the last 12 months, operating cash flow was -$60.04 million and capital expenditures $33,000, giving a free cash flow of -$60.01 million.
| Operating Cash Flow | -60.04M |
| Capital Expenditures | 33,000 |
| Free Cash Flow | -60.01M |
| FCF Per Share | -$3.55 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Neurogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3,798.26% |
| Shareholder Yield | -3,798.26% |
| Earnings Yield | -7.12% |
| FCF Yield | -10.94% |
Analyst Forecast
The average price target for Neurogene is $49.40, which is 16.90% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $49.40 |
| Price Target Difference | 16.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 19, 2023. It was a reverse split with a ratio of 1:4.
| Last Split Date | Dec 19, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |